Cover Image

Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates

Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure—driven by high prices—will be unsustainable unless further reforms are enacted.

Saved in:
Bibliographic Details
Main Authors: Espin, Jaime (Author) , Schlander, Michael (Author) , Godman, Brian (Author) , Anderson, Pippa (Author) , Mestre Ferrándiz, Jorge (Author) , Borget, Isabelle (Author) , Hutchings, Adam (Author) , Flostrand, Steven (Author) , Parnaby, Adam (Author) , Jommi, Claudio (Author)
Format: Article (Journal)
Language:English
Published: 7 August 2018
In: Applied health economics and health policy
Year: 2018, Volume: 16, Issue: 6, Pages: 803-817
ISSN:1179-1896
DOI:10.1007/s40258-018-0419-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s40258-018-0419-1
Get full text
Author Notes:Jaime Espin, Michael Schlander, Brian Godman, Pippa Anderson, Jorge Mestre-Ferrandiz, Isabelle Borget, Adam Hutchings, Steven Flostrand, Adam Parnaby, Claudio Jommi
Description
Summary:Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure—driven by high prices—will be unsustainable unless further reforms are enacted.
Item Description:Gesehen am 02.04.2020
Physical Description:Online Resource
ISSN:1179-1896
DOI:10.1007/s40258-018-0419-1

Similar Items